ANGELA GRANT: Open Payments
NPI 1649822479 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$970 in 51 payments from 15 companies in 2025. Trend: 2023 $749 · 2024 $1,017 · 2025 $970
Food & beverage: $958Education: $12
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $160 |
| Vanda Pharmaceuticals Inc. | 8 | $153 |
| Otsuka America Pharmaceutical, Inc. | 10 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $108 |
| Janssen Scientific Affairs, LLC | 2 | $65 |
| Axsome Therapeutics, Inc. | 4 | $61 |
| E.R. Squibb & Sons, L.L.C. | 3 | $59 |
| Lundbeck LLC | 2 | $50 |
| Janssen Pharmaceuticals, Inc | 2 | $40 |
| Neurocrine BioSciences, Inc. | 1 | $24 |
Products named: FANAPT, AUSTEDO XR, REXULTI, CAPLYTA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, Auvelity, COBENFY.
Industry payments across ID — which companies pay providers there.
